Groundbreaking Progress in Clinical Trial and Drug Discovery Programs Enhanced Technology Offering with Mindleap 2.0, its Digital Health Platform to Support the Adoption of Psychedelics into Mental Health and Inner Wellness DENVER, Aug. 16, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences…


Previous articlePsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
Next articleDiamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin